ReviewCurrent rheumatology reports2010
The current state of biomarkers in systemic sclerosis.
Review in Current rheumatology reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis.The Journal of investigative dermatology · 2015Trial
- The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic Sclerosis.International journal of molecular sciences · 2022Article
- Existing and novel biomarkers for precision medicine in systemic sclerosis.Nature reviews. Rheumatology · 2018Review
- Serum biomarkers of collagen turnover as potential diagnostic tools in diffuse systemic sclerosis: A cross-sectional study.PloS one · 2018Article
- Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis.European journal of rheumatology · 2016Article
- Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.Current rheumatology reports · 2016Review
- Biomarkers of pulmonary hypertension in patients with scleroderma: a case-control study.Arthritis research & therapy · 2015Article
- Serum galectin-3 level in systemic sclerosis.Clinical rheumatology · 2014Article
- Unraveling the genetic component of systemic sclerosis.Human genetics · 2012Review
- Implications of endothelial shear stress on systemic sclerosis vasculopathy and treatment.Clinical and experimental rheumatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Scleroderma is a complex, multisystem autoimmune rheumatic disease with wide heterogeneity in phenotype and outcome. There are often coexisting ongoing pathologic processes including immune system activation, progressive fibrosis, and vascular disease in subsets of patients. Currently, it is challenging to identify patients at risk for developing adverse outcomes and to determine which patients are responding to current therapies. For these reasons, it is highly valuable to find easily measurable biomarkers that may represent ongoing disease activity or treatment response. This review examines the current state of biomarker development in systemic sclerosis and identifies areas in which further work should be directed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.